In this narrative review, the authors draw upon their experiences as both life-long learners and educators and also review literature pertaining to novel teaching methodologies developed in medical education since the start of the COVID-19 pandemic.
Long-acting injectable antipsychotics are effective for preventing relapse in schizophrenia, but in-person administration of them is a challenge during a pandemic. This report describes how a clinic successfully reduced in-person injections by 40%.
During the COVID-19 pandemic, stigma has increased the spread of the disease, as patients with COVID-19 or at-risk individuals avoided seeking health care. Here, the authors explore stigma among COVID-19 inpatients in India.
Here, the authors report 2 cases of PTSD exacerbation in the context of public masking during the COVID-19 pandemic, which was reported to be a trigger leading to inpatient psychiatric hospitalization in both patients.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”